Patients with sickle cell disease (SCD) are more susceptible to severe coronavirus disease 2019 (COVID‑19) infection, in comparison with the general population, due to the possibility that the inflammatory state, along with hypoxia and hypercoagulability may increase the risk of developing acute SCD‑related complications. The present study reports the case of a 33‑year‑old female affected by SCD, who although vacci‑ nated against COVID‑19, tested positive for SARS‑CoV‑2 and developed febrile pneumonia. During hospitalization, the patient complained about generalized intense pain, along with fever recurrence and increased inflammatory marker, procalcitonin and haemoglobin S levels. The patient was treated with an intravenous analgesic therapeutics cocktail in combination with red blood cell manual exchange procedure and broad‑spectrum antibiotic therapy, achieving the rapid resolution of pain and an improvement in the laboratory test results. From the case presented herein, it is thus suggested that patients with SCD and COVID‑19 infection need to be critically evaluated by clinicians, as such patients may develop severe outcomes, attributed to the overlap of two difficult to treat conditions.
File in questo prodotto:
Non ci sono file associati a questo prodotto.